| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 01/26/2011 | CN101953808A Antineoplastic compound deacetylase fungus epoxy ethyl ester injection and preparation method thereof |
| 01/26/2011 | CN101953806A Method for preparing nano taxol frozen-dried powder |
| 01/26/2011 | CN101953805A Method for preparing antitumor medical preparation |
| 01/26/2011 | CN101953798A Spray drying sustained-release liquid crystal nano particles containing paeonol and preparation thereof |
| 01/26/2011 | CN101953796A Method for preparing recombinant human endostatin chitosan nanoparticles for injection |
| 01/26/2011 | CN101953792A Irinotecan nano circulating liposome and preparation method thereof |
| 01/26/2011 | CN101953786A 3', 5'-cyclocytidine dilaurate ether lipsome and preparation method thereof |
| 01/26/2011 | CN101953781A Irinotecan hydrochloride liquor type injection and preparation method thereof |
| 01/26/2011 | CN101953778A Folate-targeted hydrophobic medicine-loaded polymeric vesicle and preparation method and use thereof |
| 01/26/2011 | CN101953776A Non-spherical drug-loaded particles and controlled release preparation of lactyl polymer and preparation methods thereof |
| 01/26/2011 | CN101953775A Hydrogel nanoparticles used as injectable subcutaneous implant agent |
| 01/26/2011 | CN101953774A 2-methoxy estradiol injectable hydrogel implant |
| 01/26/2011 | CN101953511A Nano selenium and germanium rich negative ion safe anti-cancer cigarette for eliminating toxic hazard of cigarette smoke |
| 01/26/2011 | CN101953499A Rehabilitation drink for female myoma of uterus |
| 01/26/2011 | CN101953497A Female ovarian cyst rehabilitation drinks |
| 01/26/2011 | CN101632696B Medicinal composition for treating malignant tumor and preparation method thereof |
| 01/26/2011 | CN101624596B External guide sequence of target c-myc cancer gene |
| 01/26/2011 | CN101543476B A naringin solid dispersion and the preparation method, and the application thereof |
| 01/26/2011 | CN101524393B Preparation method of gypenoside |
| 01/26/2011 | CN101507730B Combination of epigallocatechin-3-gallate and cerubidin and use thereof |
| 01/26/2011 | CN101492672B Sulpho-oligodeoxynucleotide with immune stimulation activity and uses thereof |
| 01/26/2011 | CN101475640B Conjugate, and preparation and use thereof |
| 01/26/2011 | CN101440379B Obtaining method and use of novel oncolytic adenovirus construct with selective tumor blockage STAT3 |
| 01/26/2011 | CN101427994B Gemcitabine-containing anti-cancer medicine sustained-release injection |
| 01/26/2011 | CN101401905B Chinese medicinal composition for treating aplastic anemia |
| 01/26/2011 | CN101380327B Anti-cancer composite sustained-release composition and preparation method thereof |
| 01/26/2011 | CN101352549B Anticancer Chinese patent medicine with functions of anti-tumor metastasis and induction of tumor cell differentiation |
| 01/26/2011 | CN101352420B Hydroxycamptothecin sustained-release microsphere and preparation method thereof |
| 01/26/2011 | CN101347513B Medicine for treating cancer |
| 01/26/2011 | CN101323569B Sesquiterpenes southernwood terpene ester AE, and extraction and purification method thereof |
| 01/26/2011 | CN101293886B Preparing method and application of white banksia rose endogenetic epiphyte product of snail optical black shell bacterium ketone A |
| 01/26/2011 | CN101259235B Compound traditional Chinese medicine preparation for treating acute myeloblastic leukemia and producing method thereof |
| 01/26/2011 | CN101250187B Fatty amido substituted methylindole quinoline derivatives as well as preparation method and use thereof as anti-tumour drugs |
| 01/26/2011 | CN101240002B Fatty acylaminoacylcytarabine conjugate, preparation method and application thereof |
| 01/26/2011 | CN101224237B Novel uses of compound seabuckthorn seed oil in preparing medicine |
| 01/26/2011 | CN101181235B Tantudinun sustained-release implantation agent for curing entity tumour |
| 01/26/2011 | CN101181231B Sustained-release implantation agent of urotrotiken |
| 01/26/2011 | CN101173294B Gene tiny chain carrier, construction method and application of the same |
| 01/26/2011 | CN101172997B Oligopeptide or its modified compound/derivant and application thereof |
| 01/26/2011 | CN101164624B Nucleic acids, polypeptides, and methods for modulating apoptosis |
| 01/26/2011 | CN101139399B Fused protein restructuring target lethal leukemia cells and preparation method and use thereof |
| 01/26/2011 | CN101117637B Strict hypoxia targeting carrier and uses thereof |
| 01/26/2011 | CN101077875B Boronic ester and acid compounds, synthesis and uses |
| 01/26/2011 | CN101058561B Diphenylurea derivative for inhibiting protein kinase, and composition and use thereof |
| 01/25/2011 | US7875728 Hydrazonopyrazole derivatives and their use as therapeutics |
| 01/25/2011 | US7875727 Benzimidazole vascular damaging agents |
| 01/25/2011 | US7875712 inhibitors of apoptosis and IL-1 beta secretion; mediate cell apoptosis and inflammation; good cell penetration and pharmacokinetic properties; [3S/R(2S)]3-[2-(Carbazol-9-yl-2-oxo-ethyl)-pentanoylamino]-5-fluoro-4-oxo-pentanoic acid |
| 01/25/2011 | US7875709 Nucleic acids encoding interleukin-18 mutants |
| 01/25/2011 | US7875631 e.g.1-(3,5-dichlorophenyl)-2-formyl-6-methoxy-1,2,3,4-tetrahydroisoquinoline; to prevent and/or treat cancer and other abnormal cell growth, and metabolic as well as blood vessel proliferate disorders, in which uncontrolled expression of insulin-like growth factor-1 receptor is observed |
| 01/25/2011 | US7875625 3-guanidinocarbonyl-2-methyl-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-ylmethyl hydrogen sulfate, inhibitory effect on an Na+/H+ exchanger; |
| 01/25/2011 | US7875614 Phthalazinones |
| 01/25/2011 | US7875603 phenyl-, pyridyl-, pyrimidyl- and purine- derivatives; anticarcinogenic agent; solid tumor: breast, colorectal, lung, prostate, and ovarian |
| 01/25/2011 | US7875601 Cancer treatment with epothilones |
| 01/25/2011 | US7875592 Sulfated oligosaccharide derivatives |
| 01/25/2011 | US7875585 Hematopoietic cell E-selectin / L-selectin ligand glycosylated CD44 polypeptide |
| 01/25/2011 | US7875290 Method and form of a drug delivery device, such as encapsulating a toxic core within a non-toxic region in an oral dosage form |
| 01/25/2011 | CA2476983C Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for treatment and management of multiple myeloma |
| 01/25/2011 | CA2468180C Anti-proliferative composition |
| 01/25/2011 | CA2457856C Sulphonated meso-tetraphenyl chlorins and their use as therapeutic agents |
| 01/25/2011 | CA2454532C Retinoid derivatives with antiangiogenic, antitumoral and proapoptotic activities |
| 01/25/2011 | CA2447765C 1-biaryl-1,8-napthyridin-4-one phosphodiesterase-4 inhibitors |
| 01/25/2011 | CA2434299C Tricyclic androgen receptor modulator compounds and methods |
| 01/25/2011 | CA2433414C Process for the isolation and purification of epothilones |
| 01/25/2011 | CA2432582C Sulfamidothienopyrimidines |
| 01/25/2011 | CA2430182C Prokaryotically produced antibodies and uses thereof |
| 01/25/2011 | CA2388468C Mediators of hedgehog signalling pathways, compositions and uses related thereto |
| 01/25/2011 | CA2385322C A substantially cell membrane impermeable compound and use thereof |
| 01/25/2011 | CA2384425C Methods and compositions for delivery of pharmaceutical agents |
| 01/25/2011 | CA2381882C Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases |
| 01/25/2011 | CA2368849C Process for preparing amine platinum complexes |
| 01/25/2011 | CA2340786C Vaccine comprising cytokine-induced heat shock proteins (hsp) |
| 01/25/2011 | CA2339834C Water soluble prodrugs of hindered alcohols or phenols |
| 01/25/2011 | CA2338186C Tumor necrosis factor-gamma |
| 01/25/2011 | CA2333833C Specific binding molecules for scintigraphy,conjugates containing them and therapeutic method for treatment of angiogenesis |
| 01/25/2011 | CA2317455C Hydroxamic and carboxylic acid derivatives |
| 01/25/2011 | CA2303509C Modified timp |
| 01/25/2011 | CA2292378C A method of inhibiting cancer cell growth using a vector expressing prb2/p130 |
| 01/22/2011 | CA2710693A1 Pharmaceutical compositions |
| 01/20/2011 | WO2011009095A1 Crystalline forms of n-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]-quin0lin-4-yl}oxy)phenyl]-n'-(4-fluorophenyl)cyclopropane-1, 1-dicarboxamide |
| 01/20/2011 | WO2011009059A2 Method of treating or preventing cancer |
| 01/20/2011 | WO2011009020A2 Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers |
| 01/20/2011 | WO2011008915A1 Pyrrolopyridine inhibitors of kinases |
| 01/20/2011 | WO2011008830A1 Pyrrolopyrazine inhibitors of kinases |
| 01/20/2011 | WO2011008788A1 Fluoro-substituted compounds as kinase inhibitors and methods of use thereof |
| 01/20/2011 | WO2011008543A2 Pan-antagonists for the androgen receptor and androgen receptor mutants associated with anti-androgen withdrawal |
| 01/20/2011 | WO2011008305A1 Rna antagonists targeting gli2 for the treatment of leukemia |
| 01/20/2011 | WO2011008172A1 9e-15-(2-pyrrolidin-1-yl-ethoxy)-7,12,25-trioxa-19,21,24-triaza- tetracyclo[18.3.1.1(2,5).1(14)18)]hexacosa-1(24),2,4,9,14,16,18(26),20,22-nonaene citrate salt |
| 01/20/2011 | WO2011008110A1 3-hydroxypyrrolidine inhibitors of 5'-methylthioadenosine phosphorylase and nucleosidase |
| 01/20/2011 | WO2011007876A1 Nucleic acid molecule capable of binding to hmgb1, and use thereof |
| 01/20/2011 | WO2011007870A1 2-[[[2-[(hydroxyacetyl)amino]-4-pyridinyl]methyl]thio]-n-[4-(trifluoromethoxy)phenyl]-3-pyridinecarboxamide benzene- sulfonate, crystals of same, polymorphs thereof, and processes for production thereof |
| 01/20/2011 | WO2011007853A1 Monoclonal antibody for cancer-specific isoform |
| 01/20/2011 | WO2011007801A1 Anti-cancer agent, method for inducing apoptosis of cancer cells, and method for screening for anti-cancer agent |
| 01/20/2011 | WO2011007795A1 Composition for inhibiting the expression of target gene |
| 01/20/2011 | WO2011007794A1 Zeolite and sericite-containing composition for medical or medical assisting uses |
| 01/20/2011 | WO2011007787A1 Cancer therapeutic agent comprising antibody against cancer-specific membrane antigen |
| 01/20/2011 | WO2011007722A1 3-substituted-2-furancarboxylic acid hydrazide derivative and pharmaceutically acceptable salt thereof |
| 01/20/2011 | WO2011007633A1 Crystals of pyrroloquinolinequinone sodium salts |
| 01/20/2011 | WO2011007208A1 Compounds and methods for the treatment of cancer |
| 01/20/2011 | WO2011007145A1 Phthalazinone compound as parp inhibitor |
| 01/20/2011 | WO2011007091A1 Derivatives of 5,6-bisaryl-2-pyridine-carboxamide, preparation thereof, and therapeutic use thereof as urotensin-ii receptor antagonists |